Nasus Pharma Ltd. CEO Issues 2025 Letter to Shareholders Highlighting Progress and 2026 Milestones

Nasus Pharma Ltd. issued a press release on December 22, 2025, detailing their 2025 progress and 2026 outlook. The company focused on developing innovative intranasal products, particularly NS002, an investigational intranasal epinephrine powder formulation designed as a needle-free alternative to traditional epinephrine autoinjectors for anaphylaxis treatment. Key 2025 achievements include positive early clinical trial data for NS002, a successful $10 million IPO in August, and expanded collaborations with Aptar France S.A.S. and AptarGroup Inc. to support NS002's development and commercialization. Nasus Pharma also received Health Canada authorization to initiate a Phase 2 clinical study for NS002, with an interim analysis expected in early Q1 2026. The company outlined its 2026 milestones, including topline readout for the NS002 Phase 2 study, IND submission, pivotal study initiation, and pediatric study initiation. They also plan to initiate first-in-human studies for other pipeline products. Nasus Pharma emphasized the potential of its proprietary Nasax powder technology for fast, needle-free drug delivery in emergency medical conditions. The company also provided an overview of its business, its lead product candidate NS002, and forward-looking statements regarding its development and commercialization plans.